Triple

T12172975
Position Surface form Disambiguated ID Type / Status
Subject David Sinclair E290015 entity
Predicate coFounded P104 FINISHED
Object Genocea Biosciences
Genocea Biosciences is a biotechnology company that develops T cell–targeted vaccines and immunotherapies using a proprietary antigen discovery platform.
 E967267 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Genocea Biosciences | Statement: [David Sinclair, coFounded, Genocea Biosciences]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Genocea Biosciences
Context triple: [David Sinclair, coFounded, Genocea Biosciences]
  • A. Nautilus Biotechnology
    Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
  • B. Innogen
    Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
  • C. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • D. Genex
    Genex is an airline that uses Minsk National Airport as a primary base of operations for its flight network.
  • E. Juno Therapeutics
    Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Genocea Biosciences
Triple: [David Sinclair, coFounded, Genocea Biosciences]
Generated description
Genocea Biosciences is a biotechnology company that develops T cell–targeted vaccines and immunotherapies using a proprietary antigen discovery platform.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Genocea Biosciences
Target entity description: Genocea Biosciences is a biotechnology company that develops T cell–targeted vaccines and immunotherapies using a proprietary antigen discovery platform.
  • A. Nautilus Biotechnology
    Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
  • B. Innogen
    Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
  • C. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • D. Genex
    Genex is an airline that uses Minsk National Airport as a primary base of operations for its flight network.
  • E. Juno Therapeutics
    Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6ab4d6c00819095a9a7c35de83cfb completed April 8, 2026, 7:23 p.m.
NER Named-entity recognition batch_69d915dab42881908e2580c631d4d1cf completed April 10, 2026, 3:23 p.m.
NED1 Entity disambiguation (via context triple) batch_69f5f6a6de3081908e5e0030c081d5a4 completed May 2, 2026, 1:05 p.m.
NEDg Description generation batch_69f603b639208190a284fcd7e88e9d54 completed May 2, 2026, 2:01 p.m.
NED2 Entity disambiguation (via description) batch_69f60491eaec8190a16472fd37740ea0 completed May 2, 2026, 2:05 p.m.
Created at: April 8, 2026, 9:50 p.m.